Results from the SOUL Trial: The Cardiologists' Perspective
Diabetes Insights - Breakthroughs and InnovatorsShow Notes
Last week we heard the diabetologist's perspective on cardiovascular outcomes. In this weeks episode, EASD TV continues its deep dive into major clinical trials with the cardiologist’s perspective. Cardiologist Dr. Matthew Cavender (University of North Carolina) joins Vivienne Parry to unpack the SOUL trial, a major cardiovascular outcomes study evaluating oral semaglutide in people with type 2 diabetes.
The trial followed more than 8,000 high-risk participants and demonstrated a 14% reduction in major cardiovascular events, including cardiovascular death, myocardial infarction and stroke. Dr Cavender explains why having an effective oral GLP-1 receptor agonist is an important development for both diabetes and cardiovascular care, and what the findings mean for clinical practice, guideline implementation, and patient access.
From cross-disciplinary teamwork to the future of evidence-based prescribing, this episode offers a clear look at how the SOUL trial is shaping modern treatment strategies.
More from Diabetes Insights - Breakthroughs and Innovators
In this EASD TV interview, Prof. Zachary Gerhart-Hines (Novo Nordisk Foundation Center for Basic Metabolic Research), 61st EASD Minkowski Prize recipient, discusses research into the neurokinin-2 receptor (NK2R) and its potential to change how we approach weight management and metabolic health. Where many existing treatments focus on reducing food intake, NK2R activation could offer a complementary strategy by increasing energy expenditure, influencing appetite and improving insulin sensitivity.
How does exercise stimulate glucose uptake in muscle and what can this teach us about treating type 2 diabetes?
Prof. Anette-Gabriele Ziegler, this year’s Claude Bernard Prize Lecture recipient, reflects on her career in type 1 diabetes research and the evolution of our understanding of the disease.
The EASD’s first clinical practice guideline on the assessment and management of diabetes distress in adults living with type 1 or type 2 diabetes has now been published in Diabetologia.
How can people living with diabetes help shape the future of diabetes care?